Tag: Region Basel

  • Basel receives multi-billion euro immune research institute

    Basel receives multi-billion euro immune research institute

    The Botnar Foundation has donated one billion Swiss francs to establish the Botnar Institute of Immune Engineering (BIIE). This institute will be located in Basel, more precisely in Allschwil, and aims to develop novel immune-based solutions for the diagnosis, treatment and prevention of diseases. The BIIE is being set up in collaboration with the University of Oxford and ETH Zurich, with other international partners to follow.

    Strategic choice of location and expansion plans
    The research centre in Basel was able to prevail over renowned locations in the USA, England, Israel and Singapore. By 2027, the BIIE will move into its own building in the Switzerland Innovation Park Basel Area in Allschwil, which is being designed by Herzog & de Meuron. For the time being, the institute is housed in the Department of Biosystems Science and Engineering at ETH Zurich in Basel. It is planned that a total of 300 employees, including scientists and support staff, will work at the institute.

    Priorities and international collaborations
    BIIE will focus on the development of computer tools and immune-based solutions. Together with the University of Oxford, the Basel-Oxford Centre of Immune Engineering will be established, which will include professorships and training programmes for students. This collaboration will advance basic and clinical research, particularly for children and adolescents in poorer countries.

    Leading personalities and administration
    Stephen Wilson, former Chief Operating Officer of the La Jolla Institute for Immunology, will serve as CEO of BIIE. Sai Reddy, Professor of Systems and Synthetic Immunology at ETH Zurich, will serve as Scientific Director. Georg Holländer, an expert in molecular developmental immunology with professorships at the University of Basel, ETH Zurich and the University of Oxford, will assume the position of Global Engagement Director.

    Significant upgrade for Basel as a research centre
    The establishment of the BIIE represents a significant upgrade for Basel as a research centre. The site complements existing research groups at the D-BSSE and the Department of Biomedicine at the University of Basel and strengthens the region, which is already home to over 40 biotech and pharmaceutical companies in the field of immunology.

    Huge benefit for the Basel region
    “The BIIE will bring together a critical mass of researchers who are all experts in different aspects of immune engineering. The combination of their strengths and perspectives should result in a sum that is greater than its parts,” explains Stephen Wilson. Conradin Cramer, President of the Government of the Canton of Basel-Stadt, emphasises the importance of the institute for the region: “Basel as a strong economic region with a great philanthropic tradition will be further strengthened by the BIIE.”

    Christof Klöpper, CEO of Basel Area Business & Innovation, sees the BIIE as an enormous gain for the region: “Our life sciences location will not only be expanded by an important field of research, but will also strengthen its position on the global map of the most important research locations.”

    The generous donation from the Botnar Foundation and the collaboration with leading international institutions such as the University of Oxford and ETH Zurich position the Botnar Institute of Immune Engineering as a central institution in immune research. The new institute will further establish Basel as a top global centre for life sciences and enable significant advances in immune-based diagnostics and therapy.

  • Basel Area reaches new milestone with settlement of LifeMine

    Basel Area reaches new milestone with settlement of LifeMine

    Basel Area Business & Innovation , the agency for location promotion and innovation promotion, has reached a new milestone. With LifeMine Therapeutics , the 200th company has now been supported in settling in the Basel area. The biotechnology company has its headquarters in Cambridge in the US state of Massachusetts and is now establishing its European headquarters in the Basel Area, which consists of the three cantons of Basel-Stadt, Basel-Landschaft and Jura.

    “Having LifeMine Therapeutics as our 200th customer is very exciting for our team and the region,” said Christof Klöpper, CEO of Basel Area Business & Innovation. “The fact that LifeMine Therapeutics comes from the Boston Area – one of the world’s largest life sciences centers – underscores the opportunities that the Basel Area offers international biotech companies.”

    LifeMine develops drugs based on genetically encoded small molecules and will now also drive this work from Basel. “We are very pleased to be able to expand our activities to Basel and settle in a region full of innovative companies,” says co-founder and Chief Operating Officer (COO) WeiQing Zhou. “Basel Area Business & Innovation gave us fantastic support and made the process as smooth as we could have wished for.”

    Of the 200 companies supported by Basel Area since 2016, 164 are not from Switzerland. A total of 122 work in the life sciences. In the meantime, however, more and more companies from the production and process technology sectors are deciding to settle in the Basel area.